Chimeric, humanized, or human antibody 2A4
US7928203B2 · kind B2 · utility
20Cited by
8References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 29, 2008 |
| Grant date | Apr 19, 2011 |
| Priority date | — |
| Expiry date | Aug 18, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.